# Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

> **NCT00004032** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Ovarian Epithelial Cancer

## Interventions

- **BIOLOGICAL:** ALVAC-hB7.1
- **BIOLOGICAL:** recombinant interferon gamma
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00004032
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004032, "Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00004032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*